At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating CFZ533, Placebo to CFZ533, and 9 other interventions for Hidradenitis Suppurativa. Active but no longer recruiting, targeting 248 participants across 36 sites in 11 countries.
Detailed Summary
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.
Study Details
Timeline
Interventions
CFZ533 600 mg administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
Placebo administered subcutaneous (s.c) weekly for 4 weeks, followed by bi-weekly until Week 15.
LYS006 20 mg administered orally twice per day until Week 16.
Placebo administered orally twice per day until Week 16.
MAS825 300 mg administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
Placebo administered s.c. bi-weekly for 4 weeks, followed by monthly until Week 13.
LOU064 25 mg administered orally twice per day until Week 16.
LOU064 100 mg administered orally twice per day until Week 16.
Placebo administered orally twice per day until Week 16.
VAY736 300 mg administered s.c every 4 weeks until Week 13.
Placebo administered s.c every 4 weeks until Week 13.